1st Patient Dosed in Phase 2 Trial of Investigational PTG-200 for Crohn’s Disease, Protagonist Announces

1st Patient Dosed in Phase 2 Trial of Investigational PTG-200 for Crohn’s Disease, Protagonist Announces
The first patient has been dosed in Protagonist Therapeutics’ Phase 2 clinical trial of PTG-200 for the treatment of moderate to severe Crohn's disease, the company announced. Still recruiting at 99 sites around the world, the randomized, placebo-controlled PRISM trial (NCT04102111) is evaluating the efficacy of twice-daily dosing of PTG-200 in 90 patients with moderate to severe Crohn's disease. Protagonist Therapeutics and Janssen Research & Development are working together to develop PTG-200 through the completion of the proof-of concept-study. "We are pleased to be progressing PTG-200 in collaboration with Janssen in a Phase 2 study in patients with Crohn's disease," Dinesh V. Patel, PhD, Protagonist's president and CEO, said in a press release. PTG-200 is an interleukin-23 (IL-23) receptor (IL-23R) inhibitor, designed to block the IL-23 pathway, helping fight inflammation in patients with inflammatory bowel disease (IBD). IL-23 is an inflammatory compound called a cytokine that is secreted by immune cells and known to cause inflammation, particularly in the context of IBD. There are several available antibody treatments that target the IL-23 pathway in patients with IBD. PTG-200 is being developed as an alternative to these current injectable treatments as a safer and more tolerable therapy. Additionally, as an oral treatment, patients may be more likely to stick to a treatment plan with PTG-200 than therapies given through injection. Of particular importance, PTG-200 is restricted to the gut, which means there is a lower chance of any off-target effects in other tissues of the body. "We believe this gut-restricted oral therapy may offer meaningful advantages over injectable therapeutics currently available for Crohn's disease and othe
Subscribe or to access all post and page content.